'Flat is the new up': After biotech correction, venture investors turn to safer bets

[cafead]

via The biotech downturn that began last year had two phases: an “appropriate correction” followed by an “overcorrection,” according to Christiana Bardon, co-managing partner of BioImpact Capital and portfolio manager at MPM Capital.

article source